Colleagues Connect

SUMMER 2017

The Polyclinic’s newly renovated and expanded clinic at Northgate Plaza opens on Monday, August 28, 2017. The 62,000-square-foot facility spans three floors and will house 31 specialties including a full-service lab and diagnostic imaging department. The Polyclinic will close its Northgate Meridian location at 11011 Meridian Ave. N. and move all physicians and staff into the new clinic at 9709 Third Ave. N.E., a few blocks south of Northgate Mall. Most providers start seeing patients at Northgate Plaza on August 28.

The Polyclinic Northgate Plaza is a part of a two-year expansion plan to meet the needs of a growing North Seattle population and better serve Polyclinic patients in the North end. Over the last year, 11 family medicine providers and eight specialists moved into the renovated second floor office space at Northgate Plaza. This summer, 47 additional providers will join them.

- **First floor:** Diagnostic Imaging
- **Second floor:** Colorectal Surgery, Dermatology, Family Medicine, Gastroenterology, General Surgery, Nephrology, Neurology, OB/GYN, Pediatrics, Polyclinic NOW walk-in clinic, Sleep Medicine, and Urology
The Polyclinic supports clinical research and has been offering our patients access to clinical trials for more than six years. Many of these trials involved therapies that have since been FDA approved and are now available treatment options. Many others have been recognized in respected scientific publications.

Most recently, Polyclinic gastroenterologist Dr. Craig Pepin’s contributions as an investigator on a multi-center Phase 2B celiac disease trial were acknowledged in Gastroenterology (2017; 152:787-798). This trial studied the effect of different dose levels of latiglutenase administered for 12 weeks on reducing mucosal injury as well as celiac disease symptom frequency and severity.

Celiac disease is a serious autoimmune disorder that affects an estimated one in 100 people worldwide. Left untreated, celiac disease can lead to additional serious health problems, including bone disorders, infertility, cancer and an increase in overall mortality. Currently the only treatment option is a strict lifelong exclusion of dietary gluten, but even highly motivated patients may still experience inadvertent or background exposures to gluten. Thus, there’s continued need for development of non-dietary therapies for patients affected by celiac disease.

The study was a critical step forward in a mission all health care providers share - to improve the lives of our patients. For additional information regarding clinical trials at The Polyclinic, including Dr. Peggy Headstrom’s upcoming ulcerative colitis trial, please contact 206.860.5433 or research@polyclinic.com.